WO2024254043A3 - Nmda-r activating peptides in inflammation and neuronal differentiation - Google Patents

Nmda-r activating peptides in inflammation and neuronal differentiation Download PDF

Info

Publication number
WO2024254043A3
WO2024254043A3 PCT/US2024/032364 US2024032364W WO2024254043A3 WO 2024254043 A3 WO2024254043 A3 WO 2024254043A3 US 2024032364 W US2024032364 W US 2024032364W WO 2024254043 A3 WO2024254043 A3 WO 2024254043A3
Authority
WO
WIPO (PCT)
Prior art keywords
nmda
inflammation
neuronal differentiation
peptides
activating peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/032364
Other languages
French (fr)
Other versions
WO2024254043A2 (en
Inventor
Steven L. Gonias
Elisabetta MANTUANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Publication of WO2024254043A2 publication Critical patent/WO2024254043A2/en
Publication of WO2024254043A3 publication Critical patent/WO2024254043A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are synthetic peptides that replicate the cell-signaling and biological activities of full-length shed prion protein (PrPc), and a synthetic 4-mer peptide (KPSK), with two Lys residues, derived from the structure of P3 peptide having sequence of QWNKPSKPKTNMKH, which have uniquely broad anti-inflammatory activity. Further disclosed are methods of treating diseases associated with innate immunity and neuroinflammation using the peptides disclosed.
PCT/US2024/032364 2023-06-07 2024-06-04 Nmda-r activating peptides in inflammation and neuronal differentiation Ceased WO2024254043A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506609P 2023-06-07 2023-06-07
US63/506,609 2023-06-07

Publications (2)

Publication Number Publication Date
WO2024254043A2 WO2024254043A2 (en) 2024-12-12
WO2024254043A3 true WO2024254043A3 (en) 2025-02-27

Family

ID=93794637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/032364 Ceased WO2024254043A2 (en) 2023-06-07 2024-06-04 Nmda-r activating peptides in inflammation and neuronal differentiation

Country Status (1)

Country Link
WO (1) WO2024254043A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090130774A1 (en) * 2005-01-13 2009-05-21 David Peretz Elisa assays using prion-specific peptide reagents
US20100291090A1 (en) * 2007-04-26 2010-11-18 Strittmatter Stephen M Prion Protein as a Receptor for Amyloid-Beta Oligomers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090130774A1 (en) * 2005-01-13 2009-05-21 David Peretz Elisa assays using prion-specific peptide reagents
US20100291090A1 (en) * 2007-04-26 2010-11-18 Strittmatter Stephen M Prion Protein as a Receptor for Amyloid-Beta Oligomers

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMARO ET AL.: "Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis", J CLIN MED, vol. 10, no. 16, 2021, pages 3571 *
BUUS ET AL.: "High-resolution Mapping of Linear Antibody Epitopes Using Ultrahigh- density Peptide Microarrays", MOL CELL PROTEOMICS, vol. 11, no. 12, 2012, pages 1790 - 1800, XP055247517, DOI: 10.1074/mcp.M112.020800 *
MAHABADI ET AL.: "Cellular Prion Protein (PrPc): Putative Interacting Partners and Consequences of the Interaction", INT J MOL SCI., vol. 21, no. 19, 2020, pages 7058 *
MANTUANO ET AL.: "A soluble derivative of PrPC activates cell -signaling and regulates cell physiology through LRP1 and the NMDA receptor", J BIOL CHEM., vol. 295, no. 41, 2020, pages 14178 - 14188, XP093004916, DOI: 10.1074/jbc.RA120.013779 *
MANTUANO ET AL.: "An LRP1-binding motif in cellular prion protein replicates cell - signaling activities of the full-length protein", JCI INSIGHT., vol. 8, no. 15, 8 August 2023 (2023-08-08), pages e170121 *
WIK ET ET AL.: "Separate mechanisms act concurrently to shed and release the prion protein from the cell .", PRION, vol. 6, no. 5, 2012, pages 498 - 509 *

Also Published As

Publication number Publication date
WO2024254043A2 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
US9062125B2 (en) Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
MX2021007434A (en) Synthetic and recombinant collagen peptides having biological activity.
CA2698780A1 (en) Use of glp-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
WO2015195509A3 (en) Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX2021006856A (en) Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases.
UY25172A1 (en) FRACTURE HEALING USING PTHRP ANALOGS
HUP0003280A1 (en) Peptides having apolipoprotein a-1 agonist activity, pharmaceutical compositions comprising thereof and their use to treat dyslipidemic disorders
WO2001096364A3 (en) Peptides that stimulate cell survival and axon regeneration
EA201990885A1 (en) COMPOSITIONS CONTAINING SHORT PEPTIDES OBTAINED FROM PEDF AND THEIR APPLICATION
Xu et al. Preparation and purification of an immunoregulatory peptide from Stolephorus chinensis of the East Sea of China
WO2017180988A3 (en) Fgf21 c-terminal peptide optimization
NZ736642A (en) Short synthetic peptide for treatment and/or prophylaxis of autoimmune and inflammatory disorders
WO2018116165A3 (en) Therapeutically active complexes
WO2021046398A3 (en) Combination antiviral therapy for measles
Moore et al. Isolation and characterisation of insulin-releasing compounds from Crotalus adamanteus, Crotalus vegrandis and Bitis nasicornis venom
CN108530527A (en) Polypeptide OA-G L21 and purification method and application thereof
PT1621633E (en) Glycoproteins produced in plants with suppressed expression of beta 1, 2-xylosyltransferase
MX2023005395A (en) Peptide formulations and methods of use.
MX2020004218A (en) Methods and compositions for inhibiting adam10 biological activities.
ES2091897T3 (en) IN VITRO PROCESSING OF FUSION PROTEINS.
WO2019148140A3 (en) Implantable biomaterials that enhance stem cell survival and function
WO2007071248A8 (en) Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
AR039973A1 (en) ANTH1 CHEMICAL ANTAGONIST, FUSION OF THE N TERMINAL OF THE HUMAN INTERLEUQUINE-2 AND THE N TERMINAL OF THE EXTRACELLULAR REGION OF THE ALFA RECEIVER CHAIN FOR HUMAN ITERFERON GAMMA
DE602005024161D1 (en) PEPTIDE WITH ANTITUMORAL EFFECT
BR112022001729A2 (en) Peptide or a pharmaceutically or cosmetically acceptable salt thereof, pharmaceutical or cosmetic composition, and, depigmenting and pigmenting compositions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 24819847

Country of ref document: EP

Kind code of ref document: A2